|
Title |
Conditions |
Interventions |
Locations |
1 |
• Cervical Cancer |
• Biological: Cervical cancer-specific CAR-T cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
2 |
Safety and Efficacy Evaluation of 4th Generation Safety- engineered CAR T Cells Targeting Sarcomas |
• Sarcoma |
• Biological: Sarcoma-specific CAR-T cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
3 |
Intervention of Engineered Immune Effector T Cells Against Lung Cancer |
• Lung Cancer |
• Biological: LC-CTLs |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
4 |
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV |
• Human Papilloma Virus |
• Biological: HPV-CTLs |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
5 |
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector |
• Beta-Thalassemia |
• Genetic: Gene-modified autologous stem cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
6 |
• Hemophilia A |
• Biological: YUVA-GT-F801 |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
7 |
• Ovarian Cancer |
• Biological: OC-IgT cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
8 |
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections |
• Pathogen Infection |
• Biological: pathogen-specific CTLs |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
9 |
• Solid Tumor |
• Genetic: 4SCAR-GD2 |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
10 |
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme |
• Glioblastoma Multiforme of Brain |
• Biological: Antigen-specific IgT cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen,
Guangdong, China |
11 |
• Bladder Cancer |
• Genetic: 4SCAR-PSMA |
• Shenzhen Second People Hospital, Shenzhen, Gongdong,
China |
|
12 |
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma |
• Multiple Myeloma |
• Biological: CAR T cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen,
Guangdong, China |
13 |
• B-cell Malignancies |
• Genetic: Therapeutic 4SCAR19 cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen,
Guangdong, China |
|
14 |
• Acute Myeloid Leukemia |
• Biological: Muc1/CLL1/CD33/CD38/CD56/ CD123-specific gene-engineered T cells |
• Zhujiang Hospital of Southern Medical University,
Guangzhou, Guangdong, China |
|
15 |
Combination CAR-T Cell Therapy Targeting Hematological Malignancies |
• B-cell Malignancies |
• Biological: 4SCAR19 and 4SCAR22 |
• Zhujiang Hospital of Southern Medical University,
Guangzhou, Guangdong, China |
16 |
• Fanconi Anemia |
• Genetic: Gene-modified autologous stem cells |
• Capital Institute of Pediatrics affiliated Children's
hospital, Beijing, Beijing, China |
|
17 |
Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector #TYF-IL-2Rg# |
• SCID, X Linked |
• Biological: TYF-IL-2Rg gene-modified autologous stem cells |
• Capital Institute of Pediatrics affiliated Children's
hospital, Beijing, Beijing, China |
18 |
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors |
• Ovarian Cancer |
• Biological: OC-EIEs |
• Jinshazhou Hospital of Guangzhou University of
Chinese Medicine, Guangzhou, Guangdong, China |
19 |
• Cervical Cancer |
• Biological: CC-EIEs |
• Jinshazhou Hospital of Guangzhou University of
Chinese Medicine, Guangzhou, Guangdong, China |
|
20 |
• Ovarian Cancer |
• Biological: OC-CTLs |
• Jinshazhou Hospital of Guangzhou University of
Chinese Medicine, Guangzhou, Guangdong, China |
|
21 |
• Lung Cancer |
• Biological: Lung cancer-specific T cells |
• Jinshazhou Hospital of Guangzhou University of
Chinese Medicine, Guangzhou, Guangdong, China |
|
22 |
• Acute Myeloid Leukemia |
• Biological: CLL-1, CD33 and/or CD123- specific CAR gene-engineered T cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
23 |
Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA) |
• Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID) |
• Genetic: TYF-ADA gene-modified autologous stem cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
24 |
• Cancer |
• Biological: engineered immune cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
25 |
• Diffuse Intrinsic Pontine Glioma or Glioblastoma |
• Biological: Immunomodulatory DC vaccine to target DIPG and GBM |
• Shenzhen Geno-immune Medical Institute, Shenzhen,
Guangdong, China |
|
26 |
• B-cell Leukemia |
• Biological: 4SCAR-CD22/CD123/CD38/ CD10/CD20/TSLPR |
• Zhujiang Hospital of Southern Medical University,
Guangzhou, Guangdong, China |
|
27 |
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells |
• Cancer |
• Biological: Engineered Immune Cells |
• QiFu Hospital of Guangzhou University of Chinese
Medicine, GuangZhou, Guangdong, China |
28 |
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders |
• Immune Related Disorder |
• Biological: clonal fetal MSCs |
• Capital Institute of Pediatrics affiliated Children's
hospital, Beijing, Beijing, China |
29 |
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies |
• T-cell Acute Lymphoblastic Leukemia |
• Biological: CD7-specific CAR gene- engineered T cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
30 |
• X-linked Adrenoleukodystrophy |
• Genetic: Intracerebral LV gene therapy |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
31 |
• Chronic Granulomatous Disease |
• Genetic: Infusion of lentiviral TYF-CGD- modified autologous stem cells |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
|
32 |
• Metachromatic Leukodystrophy (MLD) |
• Biological: Lentivirus-mediated delivery of ARSA to the CNS. |
• Lung-Ji Chang, Shenzhen, Guangdong, China |
|
33 |
• Hemophilia B |
• Biological: YUVA-GT-F901 |
|
|
34 |
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies |
• B-Cell Leukemia |
• Biological: 4SCAR19/22 T cells |
• Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China |
35 |
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia |
• B Acute Lymphoblastic Leukemia |
• Genetic: prophylactic 4SCAR19 cells |
• First people's hospital of Yunnan province, Kunming, Yunnan, China |
36 |
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS |
• Leukemia, Acute Lymphocytic (ALL) |
• Biological: Chimeric antigen receptor T cells |
• Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China |
37 |
Immunotherapy Targeting Neurofibromatosis Type II or Schwannomatosis |
•Cancer |
•Biological/Vaccine: Antigen-specific T cells CART/CTL and DCvac |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
38 |
•Covid-19 |
•Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Shenzhen Third People's Hospital
• Shenzhen Second People's Hospital
|
|
39 |
Safety and Immunity of Covid-19 aAPC Vaccine |
•Covid-19 |
•Biological: Pathogen-specific aAPC |
• Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
• Shenzhen Third People's Hospital
• Shenzhen Second People's Hospital
|
40 |
PSMA-specific CAR-T Cell Therapy |
PSMA Positive Tumors |
Biological: 4SCAR-PSMA T cells |
Shenzhen Children's Hospital
The Seventh Affilliated Hospital, Sun Yat-Sen University
Shenzhen Hospital of Southern Medical University
|
41 |
4SCAR-CD44v6 T Cell Therapy Targeting Cancer |
Cancers Which Are CD44v6 Positive |
Biological: CD44v6-specific CAR gene-engineered T cells |
Shenzhen Hospital of Southern Medical University
The Seventh Affilliated Hospital, Sun Yat-Sen University
Shenzhen Children's Hospital
|
42 |
Multi-4SCAR-T Therapy Targeting Breast Cancer |
Breast Cancer |
Biological: 4SCAR T cells |
The Seventh Affilliated Hospital, Sun Yat-Sen University |
43 |
Multi-CAR-T Cells Targeting B Cell Lymphomas |
B Cell Lymphoma (BCL) |
Biological: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 |
The Seventh Affilliated Hospital, Sun Yat-Sen University
Shenzhen Children's Hospital
|
44 |
Combination Immunotherapy Targeting Sarcomas |
SarcomaOsteoid SarcomaEwing Sarcoma |
Biological: Multiple sarcoma-specific CAR-T cells and sarcoma vaccines |
The Seventh Affilliated Hospital, Sun Yat-Sen University
Shenzhen Children's Hospital
|
45 |
4SCAR-T Therapy Post CD19 targeted Immunotherapy |
CD19 Negative B-cell Malignancies |
Biological: Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 |
ShiJiaZhuang Zhongxi Children Hospital
Shenzhen Children's Hospital
The Seventh Affilliated Hospital, Sun Yat-Sen University
|
46 |
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 |
Solid Tumor |
Biological: 4SCAR-276 |
Sun Yat-sen University
Shenzhen Children's Hospital
|
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services
Copyright © 2016 Shenzhen Genoimmune Medical Institute all rights reserved.